Please login to the form below
Naxitamab
This page shows the latest Naxitamab news and features for those working in and with pharma, biotech and healthcare.
Y-mAbs files breakthrough neuroblastoma drug in US
The BLA will cover the use of naxitamab in combination with GM-CSF – a white blood cell stimulating drug – in relapsed/refractory high-risk neuroblastoma patients. ... Y-mAbs reported new results from its main phase 3 naxitamab study at the
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- AstraZeneca joins UK pilot evaluating AI-based lung cancer diagnosis system
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- EU to revise pharmaceuticals law amid antibiotic shortages
- Medical Affairs: centre-stage in scientific engagement strategies
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- UK to introduce new regulatory framework for point of care manufacturing
- Navigating the patient experience to improve retention of clinical trial participants
- Europe’s cancer community publishes new report on transforming patient care
- Alzheimer’s Research UK welcomes government’s pledge to tackle dementia crisis
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- EU to revise pharmaceuticals law amid antibiotic shortages
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Why everyone in pharma is bending over backwards to be agile
PMHub
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
